Results 221 to 230 of about 15,511 (270)
Some of the next articles are maybe not open access.
Injectable contraception: updates and innovation
Current Opinion in Obstetrics & Gynecology, 2016Purpose of review Injectable contraception is a highly effective form of birth control that is globally popular. Recent research has focused on ways to make injectables such as depot medroxyprogesterone acetate (DMPA) more accessible and to improve the side-effect profile of injectables. This review will focus on new directions
Gillian, Schivone +2 more
openaire +2 more sources
Injectable contraception: issues and opportunities
Contraception, 2014Beginning in the 1960s depot medroxyprogesterone acetate (DMPA) injectable contraception has been widely used in family planning programs abroad especially in Africa and Southeast Asia [1]. Approved in the US for the treatment of endometrial cancer in the mid-1960s it was also used off-label for contraception [2].
Andrew M, Kaunitz +2 more
openaire +2 more sources
Injectable Long-Acting Contraceptives
Clinical Obstetrics and Gynecology, 2001This paper reviews the pharmacologic and epidemiologic data on injectable contraceptives and provides clinicians with clinical insights pertaining to counseling selection initiation and maintenance to facilitate successful use of injectable contraceptives.
openaire +2 more sources
Injectable and implantable contraceptives
Current Opinion in Obstetrics and Gynecology, 1992In December 1990, the Food and Drug Administration approved Norplant (Wyeth-Ayerst, Radnor, PA) for general US use. This approval comes during a time period when the number of contraceptors relying on sterilization has risen, echoing known dissatisfaction with other reversible methods.
openaire +2 more sources
Progestin Injectable Contraceptives
2016Depot medroxyprogesterone acetate (DMPA) is an injectable progestin-only contraceptive administered every 13 weeks. Users of DMPA can be up to 2 weeks late for their repeat injection without requiring additional contraceptive protection. DMPA is an extremely effective contraceptive agent when used consistently.
Rebecca H. Allen +2 more
openaire +1 more source
Tropical Doctor, 1975
Clinical use of depot medroxyprogesterone acetate (DMPA) over a 10-year period involving 43000 acceptors 320000 injections and 77500 woman-years of use is reported. In the Chiang Mai Thailand program 3 of every 4 new family planning acceptors elect this method. 150 mg has been injected in every 12 weeks.
openaire +1 more source
Clinical use of depot medroxyprogesterone acetate (DMPA) over a 10-year period involving 43000 acceptors 320000 injections and 77500 woman-years of use is reported. In the Chiang Mai Thailand program 3 of every 4 new family planning acceptors elect this method. 150 mg has been injected in every 12 weeks.
openaire +1 more source
Contraception 2000: Lunelle™, an Injectable Combination Contraceptive Option
Journal of Women's Health & Gender-Based Medicine, 2000Contraceptive choices for women in the United States will soon expand with the expected Food and Drug Administration (FDA) approval (in early summer 2000) of a once-a-month injectable combination contraceptive. Containing 25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate (MPA/E2C) (Lunelletrade mark/Lunellatrade mark, Pharmacia and Upjohn,
openaire +2 more sources
Self-administration of injectable contraceptives
Contraception, 2008Although depot-medroxyprogesterone represents a highly effective contraceptive, its use is associated with poor continuation rates. Although the major reason for discontinuation is menstrual irregularity, the time, expense and inconvenience of clinic visits also pose a barrier to use.
openaire +2 more sources